Menu

• Immunization, Vaccines and Biologicals
• Vaccines and diseases
• Global Vaccine Action Plan
• WHO policy recommendations
  • SAGE
  • Immunization schedules
  • Position papers
  • Advisory committees
• National programmes and systems
  • Policy and strategies
  • Service delivery
  • Linking with other interventions
  • Sustainability
  • Financing and planning
  • Supply chain
  • Workforce
• Monitoring and surveillance
  • Surveillance and burden
  • Monitoring systems
  • Data and statistics
• Quality, safety and standards
• Research and development
  • Research by disease
  • Implementation research
  • Advisory committees
• Resource materials
• Newsroom

SAGE extraordinary meeting to review the Global Vaccine Action Plan for the Decade of Vaccines (DoV)

WHO-HQ, 16-17 February 2012

Declaration of interests

All 12 SAGE members participating in the meeting updated their declaration of interest ahead of the meeting. Other meeting participants do not take part in the decision-making and are thus not required to complete a declaration of interest.

Four members reported relevant interests, which were assessed not to constitute a conflict of interest. It was concluded that all members could take part in full in all discussions. All the reported relevant interests are summarized below:

Zulfiqar A Bhutta

• Received in 2009 travel reimbursements from Sabin Institute for participation in meeting as a member of the Pneumococcal Awareness Council of Experts (PACE). This interest was assessed as personal, specific and financially insignificant*.
• His department received in March 2011 a research grant from Novartis Global Health Institute on a Phase II trial of typhoid Vi conjugate vaccination. This interest was assessed as non-personal, non-specific and financially significant*.

Juhani Eskola

• Receives consultancy fees for membership in Novartis Data Safety Monitoring Board for the Global Health typhoid vaccine development project. This interest was assessed as personal, non-specific and financially insignificant*.
• Receives consultancy fees for membership in Novartis Data Safety Monitoring Board for meningococcal vaccines. This interest was assessed as personal, non-specific and financially insignificant*.
• Received in 2009 consultancy fees for participation in Novartis Pneumococcal Vaccine Advisory Group. This interest was assessed as personal, specific and financially insignificant*.
• His organization the National Institute for Health and Welfare of Finland has a large joint research programme with GlaxoSmithKline on pneumococcal conjugate vaccines. This interest was assessed as non-personal, specific and financially significant*.
• Serves as the Chair of the Steering Committee for the Tuberculosis Vaccine Initiative funded by the European Commission as well as Bill and Melinda Gates Foundation. This interest was assessed as personal, specific and financially insignificant*.

Xiaofeng Liang

• Received in 2010 a travel grant from sanofi pasteur and PAREXEL to attend the Global Meningococcal Initiative's (GMI) scientific Secretariat's meeting. This interest was assessed as personal, non-specific and financially insignificant*.
• His institution receives funding from Chinese vaccine manufacturers for conducting clinical trials on H1N1 vaccines for which he is the principal investigator. This interest was assessed as non-personal, non-specific and financially significant*.

Claire-Anne Siegrist

• Her Department received funding from sanofi pasteur, NasVax Ltd and DBV Technologies for conducting research in vaccine adjuvants and seroepidemiology of pneumococcal infections. These interests were assessed as non-personal, specific and financially significant*.
• Developed and owns the Viavac Ltd immunization management software destined to support Swiss health care professionals to follow the official immunization recommendations. Her ownership in the enterprise generates royalties of less than 10,000 USD per annum. This interest was assessed as personal, non-specific and financially significant*.
• Received in 2007-2010 partial travel grants from sanofi pasteur and Wyeth to attend two scientific meetings on pneumococcal vaccines. This interest was assessed as personal, non-specific and financially insignificant*.
• Until 2009, received small honoraria from GlaxoSmithKline for vaccinology training of pediatricians. This interest was assessed as personal, non-specific and financially insignificant*.
• Her Department receives an unrestricted educational grant from the Mérieux Foundation and receives industry support for its Advanced Vaccinology Course and INFOVAC network. This interest was assessed as non-personal, non-specific and financially significant*.
• She has participated in industry-sponsored scientific advisory boards without remuneration. This interest was assessed as personal, non-specific and financially insignificant*.
• She is the patent holder and co-inventor of DC-Chol neonatal adjuvant, sanofi pasteur, of which profits revert to her University. This interest was assessed as personal, non-specific and financially insignificant*.
• She is the patent holder and co-inventor of Viaskin transdermal booster, DBV Technologies, of which profits revert to her University. This interest was assessed as personal, non-specific and financially insignificant*.

* According to WHO's Guidelines for Declaration of Interests (WHO expert), an interest is considered "personal" if it generates financial or non-financial gain to the expert, such as consulting income or a patent. "Specificity" states whether the declared interest is a subject matter of the meeting or work to be undertaken. An interest has "financial significance" if the honoraria, consultancy fee or other received funding, including those received by expert's organization, from any single vaccine manufacturer or other vaccine-related company exceeds 10,000 USD in a calendar year. Likewise, a shareholding in any one vaccine manufacturer or other vaccine-related company in excess of 1,000 USD would also constitute a “significant shareholding”.